The ipilimumab lesson in melanoma: Achieving long-term survival

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 387-401

  Delyon, Julie ^a,b   Maio, Michele ^c   Lebbé, Celeste ^a,b,d  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IPILIMUMAB; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; COLITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HEPATITIS; HUMAN; IMMUNE RESPONSE; LONG TERM SURVIVAL; MELANOMA; META ANALYSIS; PATIENT IDENTIFICATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROIDITIS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; MORTALITY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; MELANOMA; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84929178180     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.005     Document Type: Review

References (89)

1. C.M. Balch, J.E. Gershenwald, and S.-J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
2. W.J. Lesterhuis, Haanen JBAG, and C.J.A. Punt Cancer immunotherapy - revisited Nat Rev Drug Discov 10 2011 591 600
3. H.L. Kaufman, J.M. Kirkwood, and F.S. Hodi The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma Nat Rev Clin Oncol 10 2013 588 598
4. D.J. Schwartzentruber, D.H. Lawson, and J.M. Richards gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 2011 2119 2127
5. M.B. Atkins, M.T. Lotze, and J.P. Dutcher High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116
6. S.A. Rosenberg, J.C. Yang, and R.M. Sherry Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin Cancer Res 17 2011 4550 4557
7. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
8. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
9. M.L. Alegre, K.A. Frauwirth, and C.B. Thompson T-cell regulation by CD28 and CTLA-4 Nat Rev Immunol 1 2001 220 228
10. A.H. Sharpe, and A.K. Abbas T-cell costimulation - biology, therapeutic potential, and challenges N Engl J Med 355 2006 973 975
11. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of anti-tumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
12. A. Hoos, R. Ibrahim, and A. Korman Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy Semin Oncol 37 2010 533 546
13. P. Attia, G.Q. Phan, and A.V. Maker Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 2005 6043 6053
14. F.S. Hodi, M.C. Mihm, and R.J. Soiffer Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci 100 2003 4712
15. W.J. Urba, J.S. Weber, and S.J. O'Day Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing) ASCO Meet Abstr 26 2008 3018
16. M.A. Morse Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb Curr Opin Mol Ther 7 2005 588 597
17. F.S. Hodi, M. Butler, and D.A. Oble Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proc Natl Acad Sci U S A 105 2008 3005 3010
18. P.A. Prieto, J.C. Yang, and R.M. Sherry CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma Clin Cancer Res 18 2012 2039 2047
19. J.D. Wolchok, B. Neyns, and G. Linette Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
20. A.V. Maker, J.C. Yang, and R.M. Sherry Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma J Immunother 29 2006 455 463
21. J.S. Weber, S. O'Day, and W. Urba Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 2008 5950 5956
22. S.A. Rosenberg, J.C. Yang, and D.J. Schwartzentruber Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 1998 321 327
23. J.S. Weber, R. Dummer, V. de Pril, C. Lebbé, F.S. Hodi MDX010-20 Investigators Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma Cancer 119 2013 1675 1682
24. J.S. Weber, K.C. Kahler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 2012 2691 2697
25. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
26. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
27. J.D. Wolchok, J.S. Weber, and M. Maio Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials Ann Oncol 24 2013 2174 2180
28. D. McDermott, J. Haanen, T.-T. Chen, P. Lorigan, and S. O'Day MDX010-20 Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) Ann Oncol 24 2013 2694 2698
29. Maio M, Bondarenko I, Robert C, et al. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. J Clin Oncol. 2015 Feb 9 [Epub ahead of print].
30. D. Schadendorf, and F.S. Hodi From ECC2013 - skin cancer: ipilimumab-treated patients survive up to 10 years Nat Rev Clin Oncol 10 2013 669
31. D. McDermott, C. Lebbé, and F.S. Hodi Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma Cancer Treat Rev 40 9 2014 1056 1064
32. A.M. Di Giacomo, R. Danielli, and L. Calabrò Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) Cancer Immunol Immunother 60 2011 467 477
33. J. Delyon, C. Mateus, and D. Lefeuvre Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival Ann Oncol 24 2013 1697 1703
34. P.A. Ascierto, E. Simeone, and V.C. Sileni Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort J Transl Med 12 2014 116
35. S. Wilgenhof, S. Du Four, and F. Vandenbroucke Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma J Immunother 36 2013 215 222
36. A. Berrocal, A. Arance, and J.A. Lopez Martin Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program Melanoma Res 24 6 2014 577 583
37. F. Chasset, C. Pagès, and L. Biard Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids Eur J Dermatol 2014 Dec 12. [Epub ahead of print]
38. T.K. Eigentler, M. Schlaak, and J.C. Hassel Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions J Immunother 37 7 2014 374 381
39. K. Wiater, T. Switaj, and J. Mackiewicz Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis Contemp Oncol Pozn Pol 17 2013 257 262
40. G.Y. Ku, J. Yuan, and D.B. Page Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival Cancer 116 2010 1767 1775
41. A.M. Di Giacomo, L. Calabrò, and R. Danielli Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme Cancer Immunol Immunother 62 2013 1021 1028
42. M. Altomonte, A. Di Giacomo, and P. Queirolo Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme J Exp Clin Cancer Res 32 2013 82
43. M.A. Postow, J.J. Luke, and M.J. Bluth Ipilimumab for patients with advanced mucosal melanoma Oncologist 18 2013 726 732
44. M. Del Vecchio, L. Di Guardo, and P.A. Ascierto Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma Eur J Cancer 50 2014 121 127
45. M. Maio, R. Danielli, and V. Chiarion-Sileni Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma Ann Oncol 24 11 2013 2911 2915
46. J.J. Luke, M.K. Callahan, and M.A. Postow Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience Cancer 119 2013 3687 3695
47. R. Danielli, R. Ridolfi, and V. Chiarion-Sileni Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy Cancer Immunol Immunother 61 2012 41 48
48. M.A. Deo Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients J Clin Oncol 32 2014 5s
49. V. Shahabi, G. Whitney, and O. Hamid Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab Cancer Immunol Immunother 61 2012 733 737
50. P.A. Ascierto, E. Simeone, and V.C. Sileni Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian Cohort of the Ipilimumab Expanded Access Program Cancer Invest 32 4 2014 144 149
51. R. Dummer, A. Hauschild, M. Guggenheim, U. Keilholz, and G. Pentheroudakis Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 2012 vii86-91
52. N.E.C. Schartz, C. Farges, I. Madelaine, H. Bruzzoni, F. Calvo, A. Hoos, and C. Lebbé Complete regression of a previously untreated melanoma brain metastasis with ipilimumab Melanoma Res 20 3 2010 247 250
53. K. Margolin, M.S. Ernstoff, and O. Hamid Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 2012 459 465
54. P. Queirolo, F. Spagnolo, and P.A. Ascierto Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases J Neurooncol 118 1 2014 109 116
55. M.-P. Konstantinou, C. Dutriaux, and C. Gaudy-Marqueste Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients Acta Derm Venereol 94 2014 45 49
56. A.M. Di Giacomo, P.A. Ascierto, and L. Pilla Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial Lancet Oncol 13 2012 879 886
57. J.P.S. Knisely, J.B. Yu, J. Flanigan, M. Sznol, H.M. Kluger, and V.L.S. Chiang Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival J Neurosurg 117 2012 227 233
58. A.W. Silk, M.F. Bassetti, B.T. West, C.I. Tsien, and C.D. Lao Ipilimumab and radiation therapy for melanoma brain metastases Cancer Med 2 2013 899 906
59. J.B. Macdonald Malignant melanoma in the elderly: different regional disease and poorer prognosis J Cancer 2 2011 538 543
60. V Chiarion Sileni, J. Pigozzo, and P.A. Ascierto Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme J Exp Clin Cancer Res 33 2014 30
61. O. Hamid, H. Schmidt, and A. Nissan A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma J Transl Med 9 2011 204
62. E. Simeone, G. Gentilcore, and D. Giannarelli Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma Cancer Immunol Immunother 63 2014 675 683
63. W. Wang, D. Yu, and A.A. Sarnaik Biomarkers on melanoma patient T cells associated with ipilimumab treatment J Transl Med 10 2012 146
64. M.K. Callahan, J.D. Wolchok, and J.P. Allison Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy Semin Oncol 37 2010 473 484
65. J. Yuan, M. Adamow, and B.A. Ginsberg Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Proc Natl Acad Sci U S A 108 2011 16723 16728
66. D.M. Berman, J. Wolchok, J. Weber, O. Hamid, S. O'Day, and S.D. Chasalow Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. ASCO Annual meeting 2009 J Clin Oncol 27 2009 15s (suppl; abstr 3020)
67. K. Schindler, K. Harmankaya, and D. Kuk Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab J Clin Oncol 32 2014 5s
68. J.M. Reiman, M. Kmieciak, M.H. Manjili, and K.L. Knutson Tumor immunoediting and immunosculpting pathways to cancer progression Semin Cancer Biol 17 2007 275 287
69. C. Robert, D. Schadendorf, M. Messina, F.S. Hodi, S. O'Day MDX010-20 Investigators Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control Clin Cancer Res 19 2013 2232 2239
70. B. Neyns, J.S. Weber, and C. Lebbé Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials. ASCO Annual Meeting 2013 J Clin Oncol 31 2013 (suppl; abstr 9059)
71. C. Lebbé, J.S. Weber, and M. Maio Survival follow-up and ipilimumab retreatment for patients with advanced melanoma who received ipilimumab in prior phase II studies Ann Oncol 25 11 2014 2277 2284
72. V. Chiarion-Sileni, J. Pigozzo, and P.A. Ascierto Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy Br J Cancer 110 7 2014 1721 1726
73. K.A. Margolin, O. Hamid, and J.S. Weber Ipilimumab retreatment following induction therapy: the expanded access program (EAP) experience. ASCO Annual Meeting 2013 J Clin Oncol 2013 31 (suppl; abstr 9041)
74. rems-management-guide.pdf. Available from: https://www.hcp.yervoy.com/pdf/rems-management-guide.pdf.
75. D.A. Revicki, A.J.M. van den Eertwegh, and P. Lorigan Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment Health Qual Life Outcomes 10 2012 66
76. B. Sherrill, J. Wang, S. Kotapati, and K. Chin Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma Br J Cancer 109 2013 8 13
77. S.P. Patel, W.-J. Hwu, and K.B. Kim Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma. ASCO Annual Meeting 2012 J Clin Oncol 2012 30 (suppl; abstr 8514)
78. R. Jamal, K. Belanger, and J.E. Friedmann A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM) J Clin Oncol 32 2014 5s
79. M.R. Middleton, J.J. Grob, and N. Aaronson Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 2000 158 166
80. J.D. Wolchok, H. Kluger, and M.K. Callahan Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
81. F.S. Hodi, S. Lee, and D.F. McDermott Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial JAMA 312 2014 1744 1753
82. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
83. A. Ribas, F.S. Hodi, M. Callahan, C. Konto, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
84. F.S. Hodi, D. Lawrence, and C. Lezcano Bevacizumab plus ipilimumab in patients with metastatic melanoma Cancer Immunol Res 2 2014 632 642
85. A.V. Maker, G.Q. Phan, and P. Attia Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study Ann Surg Oncol 12 2005 1005 1016
86. S.J. O'Day, M. Maio, and V. Chiarion-Sileni Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann Oncol Off J Eur Soc Med Oncol ESMO 21 2010 1712 1717
87. J. Weber, J.A. Thompson, and O. Hamid A randomized, double-blind, placebo-controlled, Phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 2009 5591 5598
88. E.M. Hersh, S.J. O'Day, and J. Powderly A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma Invest New Drugs 29 2011 489 498
89. O. Hamid, H. Schmidt, and A. Nissan A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma J Transl Med 9 2011 204